ArriVent BioPharma News

H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $25

H.C. Wainwright analyst Robert Burns maintains $ArriVent BioPharma(AVBP.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 24.0

moomoo NewsJun 6 06:33 ET

ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment

ArriVent BioPharma (AVBP) said Wednesday that it signed a collaboration agreement with Alphamab Oncology's Jiangsu Alphamab Biopharmaceuticals unit to discover, develop, and commercialize antibody dru

MT NewswiresJun 5 11:26 ET

Express News | ArriBent BioPharma Has Collaborated With Jiangsu Alphamab Biopharmaceuticals, Alphamab Oncology's Subsidiary For Cancer-focused Antibody-drug Conjugates With Upfront And Potential Milestone Payments To Alphamab Of Up To $615.5M

BenzingaJun 5 07:09 ET

Express News | Arrivent Announces a Multi-Target ADC Collaboration With Alphamab

ReutersJun 5 07:00 ET

Express News | Alphamab Oncology - Collaboration With Arrivent for Research, Development and Commercialization of ADC Products

ReutersJun 5 05:01 ET

Buy Rating Affirmed for ArriVent BioPharma on Strong Drug Trial Prospects and Strategic Advancements

TipRanksMay 20 08:25 ET

ArriVent BioPharma Welcomes Dr. Hohneker to Board

TipRanksMay 16 16:23 ET

Press Release: ArriVent Appoints John Hohneker, M.D., to Its Board of Directors

ArriVent BioPharma today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics.

Dow JonesMay 16 16:05 ET

Express News | Arrivent Appoints John Hohneker, M.d., to Its Board of Directors

ReutersMay 16 16:05 ET

Express News | HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $25 Price Target

BenzingaMay 9 07:14 ET

Buy Rating for ArriVent BioPharma Amid Strong Financials and Promising Clinical Trials

TipRanksMay 9 06:36 ET

Buy Rating Affirmed for ArriVent BioPharma on Strong Firmonernib Prospects and Financial Stability

TipRanksMay 8 15:55 ET

Express News | ArriVent BioPharma Q1 EPS $(0.70) Beats $(1.05) Estimate

BenzingaMay 8 08:15 ET

Express News | Arrivent Biopharma, Inc.: Qtrly Shr Loss $0.70

ReutersMay 8 08:07 ET

ArriVent BioPharma | 10-Q: Quarterly report

SEC announcementMay 8 08:03 ET · Announcements

Express News | Arrivent Biopharma Reports First Quarter 2024 Financial Results

ReutersMay 8 08:00 ET

ArriVent BioPharma Had Cash and Cash Equivalents of $317.4M as of March 31 >AVBP

ArriVent BioPharma Had Cash and Cash Equivalents of $317.4M as of March 31 >AVBP

Dow JonesMay 8 08:00 ET

ArriVent BioPharma 1Q Loss $17.4M >AVBP

ArriVent BioPharma 1Q Loss $17.4M >AVBP

Dow JonesMay 8 08:00 ET

ArriVent BioPharma 1Q Loss/Shr 70c >AVBP

ArriVent BioPharma 1Q Loss/Shr 70c >AVBP

Dow JonesMay 8 08:00 ET

ArriVent BioPharma Price Target Announced at $25.00/Share by HC Wainwright & Co.

ArriVent BioPharma Price Target Announced at $25.00/Share by HC Wainwright & Co.

Dow JonesApr 30 06:22 ET